Inactive Instrument

News MaxCyte, Inc. London S.E.

Equities

MXCN

USU575801258

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

MaxCyte, Inc. - Grant of Options and Restricted Stock Units	Jun. 17	AQ
MaxCyte, Inc. - Results of AGM	Jun. 13	AQ
MaxCyte, Inc. - PDMR Dealing	Jun. 12	AQ
MaxCyte CEO Maher Masoud buys 100,000 shares	Jun. 11	AN
Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing	Jun. 10	MT
MaxCyte : Participation in Upcoming Investor Conference	May. 29	PU
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference	May. 29	GL
MaxCyte inks deal with Legend Biotech for tech supply	May. 22	AN
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	May. 22	MT
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	May. 22	GL
MaxCyte, Inc. Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	May. 22	CI
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance	May. 09	AQ
MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024	May. 09	AQ
MaxCyte Shares Rise Sharply After Q1 Results Beat	May. 08	MT
MaxCyte shares rise amid double-digit revenue increase	May. 08	AN
Earnings Flash (MXCT.L) MAXCYTE Posts Q1 Revenue $11.3M	May. 08	MT
Earnings Flash (MXCT.L) MAXCYTE Reports Q1 Loss $-0.09	May. 08	MT
MaxCyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Earnings Flash (MXCT) MAXCYTE Reports Q1 Revenue $11.3M, vs. Street Est of $7.5M	May. 07	MT
Transcript : MaxCyte, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MaxCyte, Inc. London S.E.

Equities

MXCN

USU575801258

Summary

Filters